Extension usage examples:
Here's how our browser extension sees the article:
Solriamfetol for the Treatment of Excessive Sleepiness in OSA - CHEST
Source: journal.chestnet.org
Article summary:
1. This phase III randomized withdrawal trial evaluated solriamfetol (JZP-110) for the treatment of excessive sleepiness in adults with OSA.
2. The study demonstrated that solriamfetol maintained efficacy and safety over 6 weeks, with fewer participants treated with solriamfetol reporting worsening on the PGI-C from weeks 4 to 6.
3. Common adverse events included headache, dry mouth, nausea, dizziness, and insomnia.
Article analysis:
The article is a well-written and comprehensive overview of a phase III randomized withdrawal trial evaluating solriamfetol (JZP-110) for the treatment of excessive sleepiness in adults with OSA. The study was conducted in accordance with the amended Declaration of Helsinki and all participants provided written informed consent. The sample size was sufficient to provide at least 90% power to detect differences between treatments on the coprimary end points of MWT mean sleep latency time and ESS score changes from baseline to week 6.
The article is generally trustworthy and reliable, as it provides detailed information about the study design, population, outcomes, analyses, results, and safety evaluation. It also presents both positive and negative findings from the study in an unbiased manner. However, there are some potential biases that should be noted. For example, the study was funded by Jazz Pharmaceuticals Inc., which may have influenced its design or results; this should be taken into consideration when interpreting the findings of the study. Additionally, while the article does mention common adverse events associated with solriamfetol use (e.g., headache, dry mouth), it does not discuss any potential long-term risks associated with its use; this should be explored further in future studies.